Table 1 Characteristics of patients at baseline (before mepolizumab initiation)

mean ± SD

55.75 ± 13.13

Sex, no

8

 Male, no. (%)

6

 Female, no. (%)

2

Age at diagnosis (y)

51.50 ± 12.60

BMI (Kg/m²)

24.92 ± 4.10

Asthma

8

ENT involvement

8

Polyposis, no

8

 Yes, no. (%)

7

 No, no. (%)

1

Rhinosinusitis, no

8

 Yes, no. (%)

8

 Yes, no. (%)

0

SNOT-22

Mean ± SD

49 ± 22.9

TENPS no

8

Mean ± SD

3.4 ± 3.8

Polyposis surgery, no

8

 Yes, no. (%)

7

 No, no. (%)

1

Eosinophils (cell/mcl),

 Mean ± SD

2.384 ± 2.209

BVAS

 Mean ± SD

21.75 ± 6.41

ACT

 Mean ± SD

8.3 ± 2.7

FEV1%

 Mean ± SD

73 ± 24.5

Prednisone intake

Mean ± SD

16.7 ± 9

Pulmonary infiltrates

5

Peripheral nervous system involvement

3

Arthralgia/arthritis

6

Cardiac involvement

1

Glomerulonephritis

0

Ocular involvement

1

Skin involvement

4

ANCA positivity patients

2

Present and Previous treatments

OCS

7

 Azathioprine

2

 Intravenous cyclophosphamide

2

 Methotrexate

0

 Mycophenolate mofetil

2

 Omalizumab

2